MAP2K3 and lung cancer: In conclusion, we have identified several pathways (PI3K/AKT, MAPK, regulation of actin cytoskeleton, focal adhesion) and DEGs (MMP2, MMP9, FGF13, FGF12, NFKB1, PPP2R5B, PPP2R2B, CCNE2, MAPK12, FOS, MAP2K3, MAP2K6, BIRC3, BIRC2, and MLCK) associated with cisplatin resistance in lung cancer cells.